ArticleFrontiers in chemistry2025
A self-reinforcing nanoplatform for triple-synergistic therapy: NIR-triggered photothermal/gas/chemodynamic therapy of tumors.
Article in Frontiers in chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Precision Multimodal Nanodynamic Therapy for Lung Cancer: From Tumor Microenvironment-Responsive Platforms to Cell-Death Reprogramming and Immune Remodeling.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: A major challenge in nanomedicine is developing multifunctional nanoplatforms capable of achieving synergistic cancer therapy. Methods: In the present study, we developed a CD44-targeted nanocomposite, named UiO-SNO@CuS/HA, for efficacy evaluation in combination therapy including photothermal therapy (PTT), nitric oxide (NO) gas therapy and chemodynamic therapy (CDT) The nanoplatform was produced through the preparation of UiO-66-SH metal-organic framework (MOF) followed by the post-synthetic nitrosation of S-thiols to give S-nitrosothiols (SNO) as the NO donor. Afterward, in situ growth of ultrasmall CuS nanoparticles on the MOF surface led to the eventual coating of the hybrids with hyaluronic acid (HA) for active tumor targeting. Results: Under 1064 nm laser irradiation, the CuS component mediated effective PTT with a photothermal conversion efficiency of 41.4%. The generated photothermal heat also leads to the release of a considerable amount of the gas NO (135 μM, pH 4.6) and promotes the release the ions Cu Discussion: The triple-combination therapy generated by UiO-SNO@CuS/HA was demonstrated to have much higher cancer cell killing efficacy in vitro than either single or dual therapies, and very good biocompatibility with normal cells. This study reports a rationally designed feedback-amplified nanosystem that enables potent and specific triple-synergistic tumor therapy, representing a practical strategy for advanced combinatorial cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.